Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Suzhou Smartnuclide Biopharmaceutical Co., Ltd. is currently managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area, which includes 2 pending office actions. These actions are being handled by 2 distinct examiners, indicating a split in the individual reviews. Furthermore, these examiners are situated within 2 distinct art units, suggesting that the technical divisions reviewing the applications are also diversified.
The busiest examiner for the company is NICKOL, GARY B, who is responsible for 1 pending action. This 1 pending action represents half of the total 2 pending office actions currently active for the company. The fact that each of the 2 distinct examiners has an equal workload, with the busiest only having 1 pending action, shows that the company's prosecution efforts are evenly distributed across its current pipeline.
With 2 pending office actions spread across 2 distinct art units, the company is navigating multiple technical standards within the Biotechnology & Pharmaceuticals field. The involvement of 2 distinct examiners provides two different perspectives on the company's filings. Practitioners should note that NICKOL, GARY B is one of the 2 distinct examiners currently engaged, and the 1 pending action under this examiner is part of a 2-action workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| WEN, SHARON X | 1 | 56.8% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573006 | CD8ALPHA BINDING POLYPEPTIDE AND USE THEREOF | NICKOL, GARY B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573006 | CD8ALPHA BINDING POLYPEPTIDE AND USE THEREOF | NICKOL, GARY B | — |
| 18017236 | CD8 BINDING POLYPEPTIDE AND USE THEREOF | WEN, SHARON X | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573006 | CD8ALPHA BINDING POLYPEPTIDE AND USE THEREOF | NICKOL, GARY B | 1643 | §102§112Other | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18017236 | CD8 BINDING POLYPEPTIDE AND USE THEREOF | WEN, SHARON X | 1641 | §112DP | Non-Final OA | — | Pending | Sep 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Smartnuclide Biopharmaceutical Co., Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Gary B Nickol has the most, with 1 of Suzhou Smartnuclide Biopharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
